January 2026
Ayahuasca
What January 2026's 10 new studies found, synthesized from the papers below. All Ayahuasca research →
The synthesis
Synthesized from 2 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Ayahuasca, yage, hoasca, banisteriopsis, then ranked by relevance.
Research on ayahuasca published in January 2026 shows that it can enhance functional connectivity in brain networks related to social perception and cognition, and that ritualistic use combined with psychotherapeutic support is associated with significant reductions in depressive symptoms sustained for up to 180 days. However, the evidence is limited by small sample sizes (e.g., n=12 in the fMRI study) and the observational design of the longitudinal study, which lacks a control group. Overall, the findings are consistent in suggesting therapeutic potential, but confidence is constrained by the small scale and lack of controlled trials.
Confidence in the evidence
Low-Moderate- Only two empirical studies directly address the research question: one small crossover fMRI study (n=12) and one longitudinal observational study (n=280).
- The fMRI study is a well-designed crossover but has a very small sample size; the longitudinal study is observational without a control group, limiting causal inference.
- Both studies report positive effects (enhanced connectivity, reduced depressive symptoms), showing consistent direction of findings.
- No large-scale RCTs or meta-analyses were provided; the remaining studies are analytical methods, legal analyses, or theoretical reviews that do not provide clinical outcome data.
How we rate confidence
Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.
Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.
Evidence by study
Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Ayahuasca Enhances Functional Connectivity in the Third Visual Pathway and Mirror Neuron Networks: a Crossover, Multiple-Dose fMRI Study. 2026 | crossover fMRI | 12 | Supports | Ayahuasca at the highest dose significantly increased functional connectivity in the posterior superior temporal sulcus and mirror-neuron networks, correlating with enhanced social cognitive states and improved perceived social relationships at one-week follow-up. |
| The therapeutic potential of ayahuasca in depression, generalized anxiety, and substance use disorders: modulation of the depressive burden in a longitudinal study. 2026 | longitudinal observational | 280 | Supports | Ritualistic ayahuasca use combined with psychotherapeutic support was associated with a significant reduction in depressive symptoms (measured by MADRS) shortly after intervention, with improvements sustained for up to 180 days. |
Ayahuasca at the highest dose significantly increased functional connectivity in the posterior superior temporal sulcus and mirror-neuron networks, correlating with enhanced social cognitive states and improved perceived social relationships at one-week follow-up.
crossover fMRI Sample size: 12
Ritualistic ayahuasca use combined with psychotherapeutic support was associated with a significant reduction in depressive symptoms (measured by MADRS) shortly after intervention, with improvements sustained for up to 180 days.
longitudinal observational Sample size: 280
Points of agreement
- Both studies report positive effects of ayahuasca on mental health outcomes (social cognition and depressive symptoms).
- Both studies suggest that the context of use (e.g., psychotherapeutic support) may influence outcomes.
Conflicts
- No direct conflicts between the two empirical studies; however, the fMRI study focused on healthy participants and social cognition, while the longitudinal study focused on clinical populations and depressive symptoms.
Gaps
- No large-scale randomized controlled trials were provided.
- Durability of effects beyond 180 days is not addressed.
- Blinding and placebo control are absent in the longitudinal study.
- The fMRI study has a very small sample (n=12) and does not include clinical populations.
- Dose-response relationships and long-term safety are not systematically evaluated.